3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Flow Cytometry
5
Therapeutics
3
Immunologic Techniques
3
Amplified Fragment Length Polymorphism Analysis
3
ruxolitinib
2
pembrolizumab
2
abiraterone
2
Vorinostat
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Ondansetron
2
Methylprednisolone
2
Immunoenzyme Techniques
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Calcium Dobesilate
2
Aprepitant
2
Alemtuzumab
2
venetoclax
1
trametinib
1
sargramostim
1
rucaparib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pemigatinib
1
palbociclib
1
olaparib
1
neratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tinzaparin
×
Breast
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled